



August 23 – 25, 2024 OMNI Grove Park Inn, Asheville, NC

The MPN Workshop of the Carolinas aims to provide up-to-date information about the pathogenesis and management of myeloproliferative neoplasms (MPN) to practicing clinicians and will foster discussion between clinicians and scientists about management challenges and opportunities to improve outcomes for individuals with MPN.

Objectives:

- Identify optimal therapy for MPN patients.
- Analyze current knowledge of molecular response as a surrogate endpoint for clinically meaningful endpoints such as overall survival, leukemia-free survival, thrombosis-free survival in MPN.
- Discuss potential vulnerabilities of MPN stem cells or the hematopoietic stem cell niche that can be exploited to further optimize MPN treatment.

For more information, contact gina.barnard@atriumhealth.org

Follow this link to register and pay online:

https://www.southpiedmontahec.org/event/71827







August 23 – 25, 2024

OMNI Grove Park Inn, Asheville, NC





Course Directors

Ruben Mesa, MD | Atrium Health Wake Forest Comprehensive Cancer Center Naveen Pemmaraju, MD | MD Anderson Cancer Center











Co-Course Directors

Rupali R. Bhave, MD | Atrium Health Wake Forest Comprehensive Cancer Center Alexander R. Coltoff, MD | MUSC Health
Michael Grunwald, MD | Levine Cancer, Atrium Health
Brandi Reeves, MD | UNC School of Medicine
Lindsay Rein, MD | Duke Health





August 23 – 25, 2024 AGENDA

Friday, August 23, 2024

8:00 AM - 9:00 AM	BREAKFAST & VISIT EXHIBITS
9:00 AM - 9:05 AM	OPENING REMARKS & MPN UPDATES- Ruben Mesa, MD & Naveen Pemmaraju, MD
9:05 AM – 10:30 AM	Special Session #1: JAK2 & CALR: Past, Present, & Future Directions * NO CREDIT *
9:05 AM - 9:35 AM	* Keynote #1: Targeting JAK2: From Wildtype to More Specific Approaches
	Ross L. Levine, MD
9:35 PM – 10:05 AM	* Keynote #2: CALR: Marking 10 Years from Discovery to Mutant-Specific Targeting
	Jyoti Nangalia, PhD
10:05 AM – 10:30 AM	* Panel discussion: Targeting JAK2 and CALR
	Moderators: Ruben Mesa, MD & Naveen Pemmaraju, MD
	All speakers above
10:30 AM – 11:00 PM	BREAK & VISIT EXHIBITS
11:00 AM – 12:30 PM	Session #1: Inflammation, CHIP, and Disease Pathobiology in MPNs: Current and Future
	Directions - * NO CREDIT *
11:00 AM – 11:15 AM	* CHIP: Current and Future Directions
	David P. Steensma, MD, FACP
11:15 AM – 11:30 AM	* Inflammation, Dietary Factors, and the MPN Microenvironment
	Angela G. Fleischman, MD
11:30 AM - 11:45 AM	* Molecular Risk Factors for Progression in MPNs
	Rafael Bejar, MD, PhD
11:45 AM - 12:00 PM	* Leveraging Signaling Networks for the Identification of Novel Targets in MPNs
	Stephen T. Oh, MD, PhD
12:00 PM - 12:15 PM	* Inflammation and the MPNs: Reflections on COVID19 and MPNs: Lessons Learned
	Laura C. Michaelis, MD
12:15 PM – 12:30 PM	* Panel Discussion: Inflammation and Disease Pathobiology in MPNs: Relevance and Therapeutic Implications
	Moderators: Angela G. Fleischman, MD & Stephen Oh, MD
	All speakers above
12:30 PM - 1:30 PM	LUNCH & VISIT EXHIBITS





August 23 – 25, 2024

AGENDA

Friday, August 23, 2024

1:30 PM - 3:45 PM	Session #2: Focus on Translational Aspects of MPNs: The MPN-RF Spotlight Session
1:30 PM - 1:45 PM	HMGA1 and 2 in MPN: Biomarkers for Disease Progression
	Linda M. Smith-Resar, MD
1:45 PM - 2:00 PM	Different Niches for Stem Cells with the Same Oncogenic
	Simon Mendez-Ferrer, PhD
2:00 PM - 2:15 PM	Novel Biomarkers in MPN
	Vikas Gupta, MD, FRCP, FRCPath * PRESENTING REMOTELY
2:15 PM - 2:30 PM	Dissecting the Pathophysiological Role of GLUT1 in Driving Type 1 CALR-Mutated Myeloproliferative Neoplasms
	Shannon Elf, PhD
2:30 PM – 2:45 PM	The Role of Iron Deficiency, Inflammation & HIF in Thromboses of Polycythemia Vera and Essential Thrombocythemia
	Josef T. Prchal, MD
2:45 PM - 3:00 PM	Role of Gas6-Axl-MERTK in Myeloproliferative Neoplasm Thrombosis
	Joan Beckman, MD, PhD
3:00 PM - 3:15 PM	Mirabegron Study in MPNs
	Radek C. Skoda, MD
3:15 PM - 3:30 PM	JAK2.V617F Causes Lymphopenia by Blocking Lymphopoiesis
	Joseph M. Scandura, MD
3:30 PM - 3:45 PM	Panel Discussion
	Moderators: Linda M. Smith-Resar, MD & Kapila Viges
	All speakers above
3:45 PM - 4:30 PM	Special Session #2: Interferons in MPN: What is Old is New Again
3:45 PM - 4:00 PM	Interferon in Polycythemia Vera: Long Term Experience from a Single Center
	Richard T. Silver, MD * PRE-RECORDED LECTURE
4:00 PM - 4:15 PM	Updates on Ropeginterferon
	Ghaith Abu-Zeinah, MD
4:15 PM - 4:30 PM	Panel Discussion: Interferon, Molecular Response and Best Use Practices
	All speakers above
4:30 PM - 5:00 PM	CLOSING COMMENTS & FEEDBACK - Ruben Mesa, MD & Naveen Pemmaraju, MD
5:00 PM - 6:00 PM	BREAK & NETWORKING
6:00 PM - 7:30 PM	DINNER & COCKTAIL HOUR

August 23 – 25, 2024

AGENDA

Saturday, August 24, 2024

8:00 AM - 8:40 AM	BREAKFAST & VISIT EXHIBITS
8:40 AM - 8:45 AM	OPENING REMARKS
8:45 AM - 9:00 AM	RUXOPEG: Combining JAKi and IFN
	Jean-Jacques Kiladjian, MD, PhD
9:00 AM – 10:30 AM	Session # 3: ET, PV, and Special Topics in MPNs
9:00 AM - 9:15 AM	Essential Thrombocytosis in 2023: Updates
	Rupali R. Bhave, MD
9:15 PM – 9:30 AM	PV: Newer Options: From Ruxo to Ropeg to Rusfertide and Beyond
	Lindsay A.M. Rein, MD
9:30 AM – 9:45 AM	What Have Our Insights Have Our Long Term MPN Registry Studies Taught Us
	Mike Grunwald, MD
9:45AM – 10:00 AM	MPN Genomics: Focus on TP53 in MPNs -> Past, Present, and Future
	Raajit K. Rampal, MD, PhD
10:00AM – 10:15 AM	Management of Patients with MPN in Transformation to AP/BP
	Anand A. Patel, MD
10:15AM – 10:30 AM	Panel Discussion: Interferon
	Moderators: Raajit K. Rampal, MD, PhD & Rupali R. Bhave, MD
	All speakers above
10:30 AM – 12:30 PM	Session #4: Myelofibrosis: Updates on JAK inhibitors, Past, Present, and Future
10:30 AM – 10:45 AM	Prefribrotic MF: Special Considerations for a New Entity
	Prithviraj Bose, MD
10:45 AM – 11:00 AM	Anemia in MF: An Emerging Area for Therapeutic Development
	Ruben Mesa, MD
11:00 AM – 11:15 AM	Ruxolitinib in 2024 and Beyond: The Good, The Suboptimal, and the Failure
	Aaron Gerds, MD * PRESENTING REMOTELY
11:15 AM - 11:30 AM	Fedratinib in 2024 and Beyond: 2nd JAK Inhibitor Approved in MF
	Alexander R. Coltoff, MD
11:30 AM – 11:45 AM	••
	John O. Mascarenhas, MD
11:45 AM – 12:00 PM	Momelotinib in 2024: Updates and Future in MF
	Andrew Kuykendall, MD
12:00 PM – 12:30 PM	Panel Discussion: JAKi in 2024 and Beyond
	Moderator: Ruben Mesa, MD
	All speakers above
12:30 PM - 1:30 PM	LUNCH & VISIT EXHIBITS

August 23 – 25, 2024 AGENDA

Saturday, August 24, 2024

1:30 PM – 1:45 PM Novel Targeted Therapies for Myelofibrosis: Telomerase Inhibition Rami Komrokji, MD	
Rami Komrokji, MD	
1:45 PM - 2:00 PM Novel Targeted Therapies for Myelofibrosis: BET inhibition	
Lucia Masarova, MD	
2:00 PM - 2:15 PM Novel Targeted Therapies for Myelofibrosis: Targeting BCLxL in MPNs	
Naveen Pemmaraju, MD	
2:15 PM - 2:30 PM Novel Targeted Approach: XPO1 Inhibition in MPNs	
Sri K. Tanthravati, MBBS, MRCP(UK)	
2:30 PM - 2:45 PM Clinical Updates: LSD1 Inhibitors in MPNs	
Kristin M. Pettit, MD	
2:45 PM - 3:00 PM Anti-fibrotic agents in MF: Update on Novel Approaches and Therapies	
Abdulraheem Yacoub, MD	
3:00 PM - 3:15 PM Clinical Updates: MDM2 Inhibitors in MPNs	
Pankit Vachhani, MD	
3:15 PM - 3:30 PM Panel Discussion	
Moderators: Naveen Pemmaraju MD & Kristin Pettit, MD	
All speakers above	
3:30 PM CLOSING COMMENTS	





August 23 – 25, 2024 AGENDA

Sunday, August 25, 2024

8·00 AM = 8·55 AM	BREAKFAST & VISIT EXHIBITS
	OPENING REMARKS: Ruben Mesa, MD & Naveen Pemmaraju, MD
	Session #6: Stem Cell Transplantation and CAR-T/Immunotherapy in MPNs
9:00 AM - 9:15 AM	
3.00 AIVI — 3.13 AIVI	Jeanne M. Palmer, MD
9:15 AM – 9:30 AM	·
9.13 AIVI — 9.30 AIVI	Zohra Nooruddin, MD
9:30 AM - 9:45 AM	·
3.30 AIVI — 3.43 AIVI	Uday R. Popat, MD
9:45 AM – 10:00 AM	Future Directions post-SCT : Potential Applications for CAR-T and Immunotherapy in
9.45 AIVI — 10.00 AIVI	MPNs
	Tania Jain, MBBS
10:00 AM – 10:15 AM	Panel Discussion: Stem Cell Transplantation in MPNs
	Moderators: Jeanne M. Palmer, MD & Zohra Nooruddin, MD
	All speakers above
10:15 AM – 12:00 PM	Session #7: Rare and Overlap Syndromes: CMML, SM, and BPDCN
10:15 AM – 10:30 AM	Novel Therapeutic Targets in CMML
	Mrinal S. Patnaik, MD
10:30 AM – 10:45 AM	Systemic Mastocytosis: Evolution of the Field of SM
	Jason Gotlib, MD
10:45 AM – 11:00 AM	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
	Naveen Pemmaraju, MD
11:00 AM – 11:15 AM	Novel Targets in CNL and Molecular Insights
	Jeffrey W. Tyner, PhD
11:15 AM - 11:30 AM	MDS/MPN Syndromes and Atypical CML: Novel Directions
	Julia Maxson, PhD
11:30 AM – 11:45 AM	Jak2 ex13inDel CEL and Polycythemia Vera: Identification of a Novel Syndrome
	Ami B. Patel, MD
11:45 AM – 12:00 PM	Panel Discussion
	Moderators: Jason Gotlib, MD
	All speakers above

August 23 – 25, 2024 AGENDA

Sunday, August 25, 2024

1:00 PM - 2:00 PM	Session 8: MPN AYA
	Moderator: Nicole Kucine, MD, MS
1:00 PM - 1:20 PM	Special Populations in MPN: Pediatric /AYA MPN from Pediatric Perspective
	Nicole Kucine, MD, MS
1:20 PM - 1:40 PM	MPN, Fertility, and Pregnancy: Clinical Approaches and Considerations
	Gaby Hobbs, MD
1:40 PM - 2:00 PM	Thrombosis and MPNs: Clinical /Translational Updates
	Brandi Reeves, MD
2:00 PM - 2:40 PM	Special Session #3: Regulatory Considerations and Career Perspectives
2:00 PM - 2:20 PM	Perspectives on Regulatory Considerations: Disease Modification in MPNs and
	Development of Novel Clinical Endpoints
	Alison R. Moliterno, MD
2:20 PM - 2:40 PM	Career Reflections: Journey Through Academic Hematology and the MPNs
	Jerry Spivak, MD
2:40 PM - 2:50 PM	WRAP-UP: Ruben Mesa, MD & Naveen Pemmaraju, MD
2:40 PM - 2:50 PM	WRAP-UP: Ruben Mesa, MD & Naveen Pemmaraju, MD





August 23 – 25, 2024 FACULTY

Ghaith Abu-Zeinah, MD Weill Cornell Medicine, MPN Center

Assistant Professor of Medicine, Division of Hematology and Oncology New York, NY

Joan Beckman, MD, PhD

Weill Cornell University of Minnesota

Lois and Richard King Assistant Professor of Medicine Minneapolis, MN

Rafael Bejar, MD, PhD

UC San Diego Health

Associate Professor, Division of Hematology and Oncology La Jolla, CA

Rupali R. Bhave, MD

Atrium Health Wake Forest Baptist Comprehensive Cancer Center Winston Salem, NC

Prithviraj Bose, MD

University of Texas MD Anderson Cancer Center Professor, Department of Leukemia

Alexander R. Coltoff, MD

Medical University of South Carolina

Assistant Professor Charleston, SC

New Houston, TX

Shannon Elf, PhD

University of Utah Huntsman Cancer Institute

Associate Professor Salt Lake City, Utah

Angela G. Fleischman, MD, PhD

University of California, Irvine

Associate Professor Orange, CA

Aaron Gerds, MD

Cleveland Clinic

Cleveland, OH

Jason Gotlib, MD, MS

Stanford Cancer Institute

Professor of Medicine in the Division of Hematology Palo Alto, CA

Michael Grunwald, MD

Levine Cancer Institute

Chief of Leukemia Division, Director of the Transplantation and Cellular Therapy Program Charlotte, NC

Vikas Gupta, MD, FRCP, FRCPath

Princess Margaret Cancer Centre

Multidisciplinary Clinical Lead in Leukemia Professor and Barbara Baker Chair in Leukemia Ontario, Canada

Gabriela Hobbs, MD

Massachusetts General Hospital

Assistant Professor Needham Heights, MA

Ronald Hoffman, MD

Mount Sinai Hospital

Director, Myeloproliferative Disorders Research Program Albert A. and Vera G. List Professor Medicine New York, NY

Tania Jain, MBBS

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Associate Professor Baltimore, MD

Jean-Jacques Kiladjian, MD, PhD

Saint-Louis Hospital, Paris Diderot University

Professor of Clinical Pharmacology Paris, France

Rami Komrokji, MD

Moffitt Cancer Center

Senior Member & Professor of Oncologic Services, Section Head - Leukemia & MDS, Vice Chair Malignant Hematology Department Tampa, FL





August 23 – 25, 2024 FACULTY

Nicole Elena Kucine, MD, MS

Weill Cornell Medicine

Director, Pediatric Myeloproliferative Neoplasm Program, Associate Professor of Clinical Pediatrics New York, NY

Andrew Kuykendall, MD

H. Lee Moffitt Cancer Center and Research Institute

Associate Member Department of Malignant Hematology, Assistant Professor Department of Oncologic Sciences Tampa, FL

Ross Levine, MD

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College

Senior Vice President, Weill Cornell Medical College New York, NY

Lucia Masarova, MD

UT Health MD Anderson Cancer Center

Assistant Professor Houston, TX

John O. Mascarenhas, MD

Icahn School of Medicine at Mount Sinai

Director, Center of Excellence in Blood Cancers and Myeloid Disorders New York, NY

Julia Maxson, PhD

Oregon Health & Science University Knight Cancer Institute, School of Medicine Associate Professor Portland, OR

Simon Mendez-Ferrer, PhD

Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre University of Cambridge Associate Professor

Cambridge, United Kingdom

Ruben Mesa, MD

Atrium Health Wake Forest Baptist Comprehensive Cancer Center Executive Director,

Comprehensive Cancer Center

Laura C. Michaelis, MD

Medical College of Wisconsin

Chief, Professor Milwaukee, WI

Alison R. Moliterno, MD

Center for Drug Evaluation and Research, Office of New Drugs, US Food and Drug Administration, FDA

Medical Officer White Oak, MD

Jyoti Nangalia, PhD

Wellcome-MRC Cambridge Stem Cell Institute, Wellcome Sanger Institute

Principal Investigator Cambridge, United Kingdom

Zohra Nooruddin, MD

The University of Texas Health Science Center San Antonio, Mays Cancer Center

Associate Professor in the Division of Hematology-Oncology San Antonio, TX

Stephen T. Oh, MD, PhD

Washington University School of Medicine

Associate Professor of Medicine St. Louis, MO

Jeanne M. Palmer, MD

Mayo Clinic

Consultant Scottsdale, AZ

Anand A. Patel, MD

University of Chicago

Assistant Professor of Medicine Chicago, IL

Ami B. Patel, MD

University of Utah, Huntsman Cancer Institute

Assistant Professor, Division of Hematology and Hematologic Malignancies Salt Lake City, UT

Mrinal S. Patnaik, MD, MBBS

Mayo Clinic

Chair, Acute Leukemia and Chronic Myeloid Neoplasms Disease-Oriented Group Rochester, MN





August 23 – 25, 2024 FACULTY

Naveen Pemmaraju, MD

UT MD Anderson Cancer Center

Associate Professor, Department of Leukemia Bellaire, TX

Kristin M. Petit, MD

University of Michigan Health

Clinical Associate Professor Ann Arbor, MI

Uday R. Popat, MD

MD Ancerson Cancer Center

Professor Houston, TX

Josef T. Prchal, MD

University of Utah and Huntsman Cancer Center

Professor Salt Lake City, UT

Raajit K. Rampal, MD, PhD

Memorial Sloan Kettering Cancer Center

Director, Center for Hematologic Malignancies and Myeloproliferative Neoplasms Program New York, NY

Brandi Reeves, MD

University of North Carolina at Chapel Hill

Assistant Professor of Medicine Durham, NC

Lindsay Rein, MD

Duke University

Associate Professor of Medicine Hillsborough, NC

Linda M. Smith-Resar, MD

Johns Hopkins University School of Medicine

Professor, Division of Hematology Stevenson, MD

Joseph M. Scandura, MD, PhD

Weill Cornell Medicine

Professor of Medicine New York, NY

Richard T. Silver, MD

Weill Cornell Medicine, MPN Center

Professor Emeritus New York, NY

Radek C. Skoda, MD

University of Basel, The University Hospital Basel

Professor of Molecular Medicine in the Department of Biomedicine Basel, Switzerland

Jerry Spivak, MD, MACP

Johns Hopkins University School of Medicine

Emeritus Professor of Medicine Washington, DC

David P. Steensma, MD, FACP

Ajax Therapeutics

Chief Medical Officer Lincoln, MA

Srinivas Tantravahi, MBBS, MRCP(UK)

Huntsman Cancer Institute, University of Utah

Associate Professor Sandy, UT

Jeffrey W. Tyner, PhD

Oregon Health & Science University
Knight Cancer Institute, School of Medicine

Professor

Portland, OR

Pankit Vachhani, MD

University of Alabama at Birmingham

Associate Professor of Medicine, UAB Division of Hematology/Oncology Medical Director, Clinical Research Unit Birmingham, AL

Kapila Viges

MPN Research Foundation

Chief Executive Officer Chicago, IL

Abdulraheem Yacoub, MD

The University of Kansas Medical Center

Professor Leawood, KS



